A5050864170- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Immune cells in cancer
- Immune Response and Inflammation
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Inflammatory mediators and NSAID effects
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Radio Frequency Integrated Circuit Design
- PI3K/AKT/mTOR signaling in cancer
- Advancements in Semiconductor Devices and Circuit Design
- Cytokine Signaling Pathways and Interactions
- RNA Research and Splicing
- Advanced Breast Cancer Therapies
- DNA Repair Mechanisms
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- CRISPR and Genetic Engineering
- Genomics and Rare Diseases
- RNA and protein synthesis mechanisms
- Epigenetics and DNA Methylation
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Molecular Biology Techniques and Applications
Institut de Cancérologie de l'Ouest
2020-2024
Université d'Angers
2020-2023
Inserm
2020-2023
Centre National de la Recherche Scientifique
2023
Nantes Université
2020-2023
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2019-2023
Abstract In established tumors, tumor-associated macrophages (TAM) orchestrate nonresolving cancer-related inflammation and produce mediators favoring tumor growth, metastasis, angiogenesis. However, the factors conferring inflammatory protumor properties on human remain largely unknown. Most solid tumors have high lactate content. We therefore analyzed impact of monocyte differentiation. report that prolonged lactic acidosis induces differentiation monocytes into with a phenotype including...
The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing homologous recombination deficiency (HRD). However, in many countries, access to HRD is problematic the failure rate high. We developed an academic test support treatment decision-making.Genomic Instability Scar (GIScar) was through targeted sequencing a 127-gene panel determine status. GIScar trained from noninterventional study with 250 prospectively collected...
BRCA germline pathogenic variants (PV) ordefects in other genes involved HRR or MSI have been associated with sensitivity to PARP inhibitors metastatic breast cancer (mBC). Studies suggested synergy between immune checkpoint blockade and inhibition. The ER-pathway also remains a key target this setting. We evaluated the combination of olaparib, durvalumab fulvestrant ER+/HER2- mBC either somatic PV pathway, status. Patients (pts) had received 1 prior line endocrine therapy, including CDK4/6...
Targeted therapies and, more precisely, EGFR tyrosine kinase inhibitors (TKIs) have been a major improvement in the therapeutic management of EGFR-mutated non-small-cell lung cancers (NSCLCs). Earlier administration these TKIs throughout tumor progression is imperative to improve patient outcomes. Consequently, studies focused on refining characterization biomarkers, especially concerning resistance mutation p.Thr790Met EGFR. Herein, we developed peptide nucleic acid (PNA)-mediated PCR...
Abstract Background Targeted therapies in oncology are promising but variants of uncertain significance (VUS) limit their use for clinical management and necessitate functional testing vitro. Using BRCA1 BRCA2 variants, which have consequences on PARP inhibitor sensitivity, POLE potential biomarkers immunotherapy response, we developed a rapid assay based CRISPR-Cas9 genome editing to determine the these having potentially direct implications patients’ access targeted therapies. Methods We...
<h3>Introduction/Background</h3> In AOC, a better understanding of specific genomic/proteomic alterations beyond tumor BRCA mutation (tBRCAm) and homologous recombination repair deficiency (HRD) is critical importance for the next generation drug development patient outcome improvement. The main objective GREAT was to develop large AOC clinico-biological database thanks tight collaborative network between clinicians, pathologists, biologists researchers correlate real-life clinical...
TPS1116 Background: PARP inhibitors have documented clinical activity in patients with HER2 negative breast cancer (BC) and a germline pathogenic variant (PV) BRCA1 or BRCA2. Defects other genes involved homologous recombination DNA repair (HRR) mismatch pathway (microsatellite instability MSI) been associated preclinical cellular sensitivity to inhibitors. Several studies suggested synergy between immune checkpoint blockade Indeed, tumors deficiency HRR higher mutagenic potential produce...
<div>Abstract<p>In established tumors, tumor-associated macrophages (TAM) orchestrate nonresolving cancer-related inflammation and produce mediators favoring tumor growth, metastasis, angiogenesis. However, the factors conferring inflammatory protumor properties on human remain largely unknown. Most solid tumors have high lactate content. We therefore analyzed impact of monocyte differentiation. report that prolonged lactic acidosis induces differentiation monocytes into with a...
<p>Table S2</p>
<p>Figure S4</p>
<p>Figure S2</p>
<p>Figure S5</p>
<p>Table S1</p>
<p>Figure S1</p>
<p>Figure S3</p>
<p>Figure S1</p>
<p>Table S2</p>
<p>Figure S4</p>
<p>Figure S5</p>